Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06569680 · ClinicalTrials.gov registry record · Phase 2
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
A Phase 2 study of Extranodal Marginal Zone Lymphoma, sponsored by Izidore Lossos, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT06569680: Recruiting Phase 2 study of Extranodal Marginal Zone Lymphoma, sponsored by Izidore Lossos, MD.
NCT06569680 is a Phase 2 study of Extranodal Marginal Zone Lymphoma that is actively recruiting participants, run by Izidore Lossos, MD. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06569680, a Phase 2 study of Extranodal Marginal Zone Lymphoma, is actively recruiting participants, sponsored by Izidore Lossos, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer is in stage I-IV. This study will help doctors understand if Mosunetuzumab improves outcomes in people with EMZL and if it is safe to use.
Primary Outcome
The number of participants with best overall response of complete response (CR) to protocol therapy will be reported. Response will be assessed using Cheson 2014 criteria if disease is not FDG-avid in initial screening, and by revised Lugano 2014 criteria if screening Fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) (FDG PET/CT) demonstrated FDG-avid disease.
Conditions Studied
Interventions
- DRUG Mosunetuzumab
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-11-19 |
| Est. Completion | 2030-12-01 |
| Phase | Phase 2 |
What NCT06569680 shows while recruiting
NCT06569680 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Extranodal Marginal Zone Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Mosunetuzumab is the first listed.
NCT06569680 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06569680 about?
NCT06569680 is a clinical study titled "Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma". The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This study will include people who have not yet received any treatment for cancer and whose cancer is in stage I-IV. This study will help doctors und...
What is the current status of trial NCT06569680?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2024-11-19. Estimated completion is 2030-12-01.
What conditions does trial NCT06569680 study?
This clinical trial studies the following conditions: Extranodal Marginal Zone Lymphoma.
What interventions are being tested in trial NCT06569680?
The interventions under investigation include: Mosunetuzumab (DRUG).
Who is sponsoring clinical trial NCT06569680?
This trial is sponsored by Izidore Lossos, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06569680 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06569680's enrollment target sits among peer trials
35 1524th of 2000 higher than 463 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI